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Summary 
To better understand the requirement for interleukin 2 (IL-2) in specific immune responses, we 
have established  the use of cell ablation to selectively eliminate T  cells that produce IL-2.  To 
accomplish this we have generated transgenic mice that express the herpes simplex virus 1-thymidine 
kinase (HSV-TK) gene under the transcriptional control of the murine IL-2 promoter that renders 
IL-2-producing cells sensitive to the cytotoxic effects of the antiviral drug ganciclovir (GANC). 
HSV-TK activity was specifically expressed in activated  T  cells from transgenic mice.  When 
CD4 T cells from transgenic mice were stimulated with the superantigen staphylococcal enterotoxin 
A (SEA) in the presence of GANC, proliferation and IL-2 production were almost completely 
inhibited and the activated  CD4+VB3 + T  cell population, eliminated. Proliferation was not 
restored by adding IL-2, showing that most proliferating cells are not bystander cells. In contrast, 
the proliferative response to concanavalin A (Con A) was only partially inhibited by treatment 
of CD4 T cells with GANC, although the efficiency of eliminating IL-2-producing cells was 
shown to be comparable with that achieved using SEA. This suggests that a portion of the 
proliferative response to Con A occurs via an alternative  pathway not requiring IL-2 synthesis 
and release. 
T 
he proliferation of clones of antigen-specific cells is one 
of the most important events that occurs during a pri- 
mary immune response. Since the frequency of antigen-specific 
precursor T  cells is low in peripheral lymphoid organs or 
in blood, the clonal expansion of antigen-reactive effector cells 
is critical for the expression of a specific immune response. 
Such clonal expansion is accomplished by tightly regulating 
the production of specific lymphokines that can function as 
growth  factors,  and by regulating the  expression  of the 
receptors for these lymphokines (1). 
Antigen-induced T cell proliferation is regulated primarily 
through the actions of IL-2 on its specific cell surface receptor. 
IL-2 is a lymphocytotropic hormone released from antigen- 
triggered T  lymphocytes within hours of activation.  IL-2 
mediates a switch in T cells from G1 into the proliferative 
phases of the cell cycle. Once T cells are stimulated to secrete 
IL-2,  the lymphokine can interact with the same cell from 
which it was produced (an autocrine effect) or with any other 
cell that expresses IL-2 receptors (a paracrine effect), leading 
to clonal expansion (2, 3). 
Although IL-2 remains a most important factor regulating 
T cell growth, there are clearly IL-2-independent mechanisms 
that can also regulate T cell proliferation (4-8). In addition, 
murine T  helper cells can be divided into subsets based on 
the pattern of cytokines secreted in response to antigen or 
mitogen stimulation (9).  Cells of the Thl subset  produce 
IL-2,  IFN-%  and lymphotoxin, whereas Th2 cells secrete 
IL-4, IL-5, and IL-6. The different cytokines released by Thl 
and Th2 clones lead to markedly different functions (10-12). 
Whereas Thl clones require IL-2 as an autocrine growth factor, 
the growth of Th2 clones involves the autocrine secretion 
of IL-4,  as well as the cofactor IL-1 (13, 14). 
The dichotomy between T  helper cells with regard to 
cytokine production poses the question of lineage relation- 
ship between T cells that secrete different cytokines, specifically 
IL-2,  IL-4, and IFN-3,.  Although models exist  to explain 
the origins of the distinct functional subsets (15), it is un- 
known whether a given subset is derived from the other or 
if there is a common precursor cell. 
To analyze the role of IL-2-producing T  cells in T  cell 
development and in a given immune response, we generated 
transgenic mice which allow the selective ablation of IL- 
2-producing T cells in vitro. Borrelli et al. (16) showed that 
the synthesis of HSV-thymidine kinase (TK) 1 in transgenic 
mice could be used to ablate cells that express this product. 
We chose this approach because it offers several advantages 
Abbr~iations used in this paper: GANC, ganciclovir; HSV-TK, herpes 
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able, such as those that employ anti-IL-2 antibodies (17, 18) 
or IL-2-deficient mice (19). First, our approach allows us to 
determine the proportion of cells that are proliferating in a 
given immune response that are actually making IL-2 or, al- 
ternatively, are bystander cells that require IL-2 for cell growth 
but  are not making  IL-2.  Second, the transgenic mice we 
have generated are ideal for studying precursor-product rela- 
tionships between different cytokine-producing T  cells. Fi- 
nally, the ability to eliminate cells that produce IL-2 enables 
us to examine the function of these cells in a given immune 
response,  as well as during  development.  Since our ability 
to selectively ablate IL-2-producing T cells is based on a toxic 
phenotype that is cell specific and inducible,  these cells can 
be eliminated during different stages of development or of 
an immune response (i.e., during priming or during a recall 
response). More importantly, an inducible toxic phenotype 
allows us to study the function of a cell without interfering 
with  the development of that  cell. 
We establish here that ablation is specific for cells that are 
proliferating in response to mitogenic stimulation,  and that 
the cells that  are not activated or do not produce IL-2 are 
not eliminated. This new approach also reveals an interesting 
difference between the requirement for IL-2-producing cells 
in the proliferation induced by Con A versus staphylococcal 
enterotoxin A  (SEA)  stimulation. 
Materials and Methods 
Gene Constructs  and Transgenic  Mice.  The plasmid pATgMIL2-A 
containing the murine Ib2  gene was  obtained from Drs.  Erik 
Reraaut and Waiter Fiefs (University of Ghent, Belgiura) (20). The 
2.7-kb Ib2 promoter was isolated by EcoRI-Pst restriction diges- 
tion of pATgMIL2-A.  This fragment contains the TATA box and 
the DNase hypersensitive site located at - 275 that have been shown 
to be necessary for transcription (21). The IL-2 promoter was linked 
to a 1.5-kb BgllI-HindIII fragment of the HSV-1-TK gene (22) via 
a Pst-BgllI linker to generate the construct pIb2TK. 
The recombinant DNA pIL-2TK was injected into C57BL/6 
x  SJL F2 fertilized mouse eggs by the Yale Transgenic  Facility. 
Five positive founder lines were established. The founder lines were 
back-crossed onto C57BL/6 mice (The Jackson Laboratory, Bar 
Harbor, ME) to obtain progeny for these studies. 
Cell Lines.  The TK §  cell  line  was  a  generous gift  of Dr. 
Wilma Summers (Yale University, New Haven, CT) and has been 
described (23). 
Antibodies, Cytokines, and Reagents.  Supernatants from the anti- 
Thy-1 hybridoraa Y19 (24) and the raAb 212.A1 (anti-I-Ab)  (25) 
were generated at Yale University. The antibodies TIB105 (anti- 
CD8), TIB146 (anti-B220), and HB191 (anti-NK cell) were ob- 
tained from the American Type Culture Collection (gockville, MD). 
PE-conjugated anti-CD4 raAb was purchased from Becton Dick- 
inson & Co. (Mountain View, CA) and FITC-conjugated anti-V133 
mAb (KJ25)  was obtained from Pharmingen (San Diego, CA). 
Recombinant routine IL-2 (rlb2) was purchased from Boehringer 
Mannheim Corp. (Indianapolis, IN), and had asp act >--106  U/rag. 
SEA was obtained from Upjohn (Kalamazoo,  MI) and ganciclovir 
(GANC) was a gift from Syntex (Palo Alto, CA). Tetrahydrouri- 
dine (THU) was a generous gift from Dr. William Summers (Yale 
University, New Haven, CT). 
HSI/:'FK Assay.  Spleen cells were plated at 107 cells/well in 24- 
well plates  (Costar Corp.,  Cambridge,  MA) in 2 ml of EHAA 
medium with 10% FCS. T cells were obtained by depletion with 
the anti-I-Ab antibody 212.A1. B cells were obtained as described 
below. T cells were plated in the presence or absence of 2.5 #g/ml 
Con A (Boehringer Mannheim Corp.) for 42 h. B cells were stimu- 
lated with 50 #g/m1 LPS (Sigma Chemical Co., St. Louis, MO). 
Ceils were harvested and lysed in 20 #1 TK assay buffer (see below) 
containing 0.1% Triton. Cell extracts from the HSV-TK § cell line 
were used as a positive control for the assay. 
The standard assay for TK was obtained from Summers and 
Summers (23) and modified slightly. The assay included 0.1 M so- 
dium phosphate, pH 6., 0.01 M ATP, 0.01 M magnesium acetate, 
0.025  M NaF. The substrate nSI-deoxycytidine (dC) (100 #Ci/0.4 
ml; New England Nuclear, Boston, MA) was used at 0.5 #Ci per 
50/zl reaction. The dC deaminase  inhibitor THU was added to 
a final concentration of 50 #g/ml.  10 #1 ceU extract was used in 
each reaction and the assay was run at 37~  Incorporation of la- 
beled substrate was determined by absorption of 10 #1 of the reac- 
tion to DEAE paper disks  that  were washed in water 3  x  15 
rain  and in ethanol  15  rain,  air-dried,  and counted in  a liquid 
scintillation counter (model LS2800; Beckman Instruments, Inc., 
Fullerton, CA). 
Cell Growth Assay.  The cytotoxicity of the drug GANC was 
determined by using a cell growth assay. To obtain CD4-enriched 
T cells, total spleen cells were incubated for 60 rain at 4~  with 
an antibody cocktail containing T1B105 (anti-CD8), T1B146 (anti- 
B220), HB191 (anti-NK cell), and 212.A1 (anti-l-Ab). Cultures were 
subsequently incubated with magnetic anti-mouse IgG (Collabora- 
tive Research,  Inc., Bedford, MA) for 20 rain at 4~  and then 
passaged over a magnet three times. To obtain CD8-depleted cul- 
tures, the same procedure was followed except that T1B105 was 
the only antibody used. On average, 70% enrichment of CD4 cells 
was obtained. 
To deplete cultures of T cells for generating APCs, total spleen 
cells were resuspended directly in supernatant from a Y19 (anti- 
Thyl) hybridoraa and incubated for 60 rain at 4~  The cells were 
then  treated  with  rabbit  complement  (Low-Tox-M;  Cedarlane 
Laboratories Ltd., Hornby, ON, Canada) at 37~  for 30 rain. To 
obtain syngeneic APCs, complement-lysed cultures were irradiated 
(2,500 tad). 
CD4 cells from transgenic and control mice were cultured in 
a volume of 200 #1EHAA medium with 10% FCS in flat-bottomed 
96-well  plates  (Costar Corp.). Where indicated, 104 APCs were 
added to each well. Unless otherwise indicated, GANC was used 
at 10/zM, To measure proliferation for SEA (100 ng/ral)-stimulated 
cells, 1 #Ci [3H]thymidine was added on day 6 of culture and cul- 
tures were harvested on day 7 using a harvester (Pharmacia  LKB 
Biotechnology Inc., Piscataway, NJ). Ceils treated with Con A (2.5 
#g/ml) were pulsed on day 3 and harvested on day 4. 
Cytokine Assay.  The CTLb2 cell line was obtained from Dr. 
F. Fitch (University of Chicago, Chicago, IL). CTLL cells (5  x 
10  J) were incubated with dilutions of test supematants or control 
recombinant lymphokines in 96-weU plates for 42 h, pulsed with 
1 #Ci  [~H]thymidine,  and harvested  the next day. 
Flow Cytometry.  Spleen calls were treated with Gey's medium 
to lyse KBCs  and  subsequently enriched for CD4 ceils.  CD4- 
enriched cultures (106 cells/well)  and APC (10  s) were plated in 
24-well plates  and stimulated with SEA (100 ng/ral)  +  20 #M 
GANC.  Ceils were harvested on days 4 and 6 and stained  (2  x 
106 cellsAaraple) using PE-conjugated anti-CD4 mAb and FITC- 
conjugated  anti-VB3  (KJ25)  mAb  in  PBS with  1%  FCS.  The 
staining was performed at 4~  for 15 rain in 96-well plates. The 
1452  Ablation  of Ib2-producing  Cells samples were washed twice and analyzed on a FACS  |  Analyzer 1 
(Becton Dickinson  & Co.). 
In Situ Hybridization.  The Ib2 probe, kindly provided by Dr. 
V. Paetkau (University of Alberta, Alberta, Canada), corresponded 
to a full-length cDNA clone (26). In situ hybridization was carried 
out on cytocentrifuge preparations of mitogen-stimulated  CD4 T 
cells using 3sS-labeled R.NA sense or anti-sense transcripts essen- 
tially as described (26, 27). Before hybridization, stored slides were 
rehydrated, acetylated, and prehybridized at 50~  for 2 h. The slides 
were then dehydrated and hybridized at 50~  for 16 h. The hy- 
bridized slides were washed and dehydrated, and autoradiography 
was performed  as described (26). 
Results 
Spleen Cells Isolated  from Transgenic  Mice Express HSK-TK 
Activity.  To establish transgenic mice that allow the selec- 
tive ablation of IL-2-producing T cells,  the HSV-TK gene 
was placed downstream of the murine IL-2 promoter to di- 
rect expression of the HSV-TK gene (Fig.  1). The treatment 
of cells that  express HSV-TK with an antiviral agent such 
as GANC results in cell death (16). Five positive founder lines 
were identified using Southern  blot analysis. 
To determine the level of HSV-TK activity expressed, TK 
assays specific for the viral enzyme were carried out. In the 
presence of T  cell activation  and  subsequent  IL-2 produc- 
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Figure 2.  HSV-TK  activity present in spleen cells isolated from trans- 
genie mice. Spleen cells were plated  at  107 calls/well in the presence or 
absence of 2.5/*g/ml Con A. Calls were cultured for 42 h, harvested, 
and lysed in TK assay buffer containing 0.1% Triton.  Each reaction con- 
sisted of 10/A of cell extract,  0.1 M sodium phosphate  (pH 6), 0.01 M 
ATP, 0.01 M magnesium  acetate, 0.025 M NaF, 50/~g/ml THU, and 0.5 
#Ci ~2Sl-deoxycytidine  in a total volume of 50/zl. The incorporation  of 
the substrate  *~Sl-deoxycytidine  was determined  after 3 h of incubation 
at 37~  by adsorption of 10/A of the reaction to DEAE paper and counting 
on a liquid scintillation  counter.  106 TK + cells were used as a positive 
control. 
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Figure  1.  IL-2-TK construct used 
to  generate  transgenic  mice.  The 
2.7-kb murine Ib2 promoter (Imtcked 
box) was fused to the 1.5-kb coding 
sequence (stippled box)  of the HSV- 
1-TK gene by a PstI-Bglll linker. 
tion,  the HSV-TK gene should be expressed.  Total spleen 
cells were isolated from each transgenic line and cultured for 
42 h in the presence or absence of Con A; cell extracts were 
assayed for HSV-TK activity (Fig.  2). An HSK-TK positive 
cell line was used as a positive control for the assay. The trans- 
genie lines 529, 531, and 539 show substantial HSV-TK ac- 
tivity in the presence of Con A  as compared with  the B6 
control.  In  the 529 pedigree (which has  the highest  copy 
number), expression of HSV-TK appears to be at least partly 
constitutive since HSV-TK activity can be detected in the 
absence of Con A stimulation. Two other founder lines, 536 
and 726, had low to zero HSV-TK activity (data not shown). 
Cell-specific Expression of nSV-TK Activity.  To determine 
whether the transgene was expressed specifically  in T  cells, 
total spleen cells were isolated from the 539 pedigree and sepa- 
rated into T and B cells. T cells were cultured in the presence 
or absence of Con A  and B  cells were incubated with  or 
without LPS. Significant  TK activity was only present in cell 
extracts prepared from T cells stimulated with Con A (Fig. 
3), not in transgenic B cells or B6 control cells. The B and 
T cells were activated by LPS and Con A, respectively, since 
they proliferated in response to the specific stimulus (data not 
shown). 
Specific Killing ofT Cells Isolated  from Transgenic  Mice Using 
GANC.  To evaluate the e~cacy of our system, the toxicity 
of GANC to T cells expressing the HSV-TK gene was tested 
in vitro. For GANC to kill T cells, the IL-2 promoter must 
be activated to allow HSV-TK expression. Though it is not 
dear to what extent chromosomal damage must occur to re- 
sult in cell death,  toxicity is very likely dependent on both 
GANC  concentration  and  length  of treatment.  For  these 
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Figure  3.  HSV-TK activity in T and B cells. Total T and B cells were 
obtained as described  in Materials and Methods.  107 T  or B cells were 
cultured with 2.5/xg/ml Con A or 50 #g/ml LPS, respectively, for 42 h. 
Cells were harvested and lysed in assay buffer and 50-/~1 reactions were 
run as described in the legend to Fig. 2. The incorporation of the substrate 
12SI-deoxycytidine was determined after 3 h of incubation at 37°C by ab- 
sorption of 10/~1 of the reaction to DEAE paper and counting on a liquid 
scintillation counter.  106 TK + cells were used as a positive control. 
reasons, SEA was chosen for T  cell activation.  SEA is a su- 
perantigen which, when combined with MHC class II mol- 
ecules, is a powerful stimulator of T cells via the VB element 
of the TCR (28). When unprimed splenic T cells are incubated 
in the presence of SEA, maximum proliferation is accompa- 
nied by a large production of IL-2 (data not shown). GANC 
treatment  suppressed proliferation  to SEA of CD4 T  cells 
from transgenic lines 529, 531, and 539 (Fig. 4) showing that 
the proliferating cell has been ablated. Proliferation of T cells 
from the control B6 mouse is not inhibited in the presence 
of the drug.  The transgenic lines 539 and 529 were chosen 
for their high HSV-TK activity and sensitivity to GANC. 
However,  since the  529 pedigree shows some constitutive 
HSV-TK activity (Fig.  2), most experiments  in this study 
were performed using the  539 mice. 
Titration of GANC Concentration.  To determine the op- 
timum concentration of GANC, CD4-enriched T  cells de- 
rived from 539 transgenics and control mice were cultured 
in the presence of SEA and various concentrations of GANC 
(Fig.  5).  Suppression was partial  at  1 #M GANC but in- 
creased to 89% at 10/~M GANC in CD4 cells from the trans- 
genic mouse. An insignificant level of nonspecific inhibition 
(4%) of cells from the control mouse also occurred at 10/~M 
but  increased  significantly at  50-100 #M  GANC.  Similar 
results were observed with total spleen cells (data not shown). 
A concentration of 10/~M GANC was therefore selected for 
this  study (unless otherwise noted). 
Titration of Cell Number.  The inhibitory effect of GANC 
on the ability of CD4 T  cells  to proliferate in response to 
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Figure  4.  Suppression of proliferation in the presence of GANC. Spleen 
cells were depleted of CD8 cells and plated at 2.5  x  104 cells/well. Cells 
were activated using 100 ng/ml SEA in the presence or absence of 10/~M 
GANC. Cells were pulsed with [3H]thymidine (1/~Ci) on day 6 and in- 
corporation was measured on day 7. Samples were run in duplicate and 
the maximum average cpm obtained was  189,634. 
SEA is titratable with cell number (Fig.  6). The suppression 
of proliferation  ranged  from  85%  using  5  x  104 cells  to 
98% using 1.25  x  104 cells.  These results further demon- 
strate the importance of IL-2-producing cells in the prolifer- 
ative response to SEA. 
Elimination of lL-2 Production by the Ablation of TK-Expressing 
Cells.  As an additional estimate of the effaciency of elimina- 
tion of IL-2-producing cells, we stimulated IL-2-TK T cells 
with SEA plus or minus GANC and determined the amount 
of IL-2 produced as a function of input  cell number  (Fig. 
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Figure  5.  Titration of GANC concentration. 5  x  104 CD4-enriched 
spleen cells were cultured in the presence of 100 ng/ml SEA and various 
concentrations of GANC. 104 APC were added to each well and cells were 
pulsed with [3H]thymidine on day 6 and harvested on day 7. Samples were 
run in duplicate and the maximum average cpm obtained was  89,352. 
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Suppression of proliferation is titratable with cell number. 
Various numbers of CD4-enriched spleen cells were cultured with 100 
ng/ml SEA and 104 APC in the presence or absence of 10/zM GANC. 
Cells were pulsed with [3H]thymidine  (1/~Ci) on day 6 and incorpora- 
tion was measured on day 7. Samples were run in triplicate and the SE 
is given. The maximum average cpm obtained was 347,305. 
Table  1.  Effect of GANC on the V~3 + T  Cell Population 
B6  Transgenic 
-  Drug  + Drug  -  Drug  + Drug 
Day 4 
Day 6 
CD4+VB3 -  13.4  12.2  11.7  4.9 
CD4 +  VB3 +  5.6  6.9  5.3  1.0 
CD4-V~3-  71.9  70.5  70.5  86.2 
CD4-VB3 §  9.1  10.5  12.6  8.0 
CD4+VI33 -  8.4  9.0  12.1  5.0 
CD4+VI33 +  5.7  4.9  7.3  4.1 
CD4-VI33-  57.3  61.3  53.3  60.2 
CD4-VB3 +  28.6  24.7  27.3  30.7 
Shown are the percent cells present in different populations before and 
after GANC  treatment  of SEA-stimulated cultures. Values were de- 
termined  by  FACS  |  analysis. The percentage of CD4+VB3 +  and 
CD4-VB3 + cells present in the starting population were 0.52 and 5.92, 
respectively. 
7). The presence of GANC in the culture medium reduced 
the IL-2 secreted by about  80-90%.  The efficiency of the 
IL-2-TK system is therefore ",,80-90%, whether measured 
by elimination of proliferation (Fig. 6), IL-2 production (Fig. 
7), or the elimination of cells expressing IL-2 mRNA mea- 
sured by in situ  hybridization  (see Table 2). 
V/33  T  Cells Activated  by SEA  Are Specifically Killed by 
GANC.  T cells bearing VB3 receptors proliferate specifically 
in the presence of SEA (29). Since the strain of mouse used 
in this study is VB3 +, T  cells were analyzed by FACS  |  to 
determine if GANC treatment of SEA-stimulated cells resulted 
in a loss of this T cell population. CD4-enriched T cells were 
stimulated with SEA in the presence or absence of 20 #M 
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Figure 7.  ID2 production of CD4 T cells treated with GANC. Var- 
ious numbers of CD4-enriched spleen cells were cultured with 100 ng/ml 
SEA and 104 APC in the presence or absence of 10/~M GANC. Culture 
supematants were collected on day 3 and assayed for the presence of Ib2 
by the induction of CTLL-2 proliferation. 
GANC,  harvested on days 4  and 6,  and double stained for 
CD4 and V/33 expression (Table 1, Fig. 8). Using this scheme, 
the  cells  were  divided  into  CD4+V33 +,  CD4+V33 -, 
CD4- V/33-,  and  CD4- V~3 +  populations. 
As  expected,  the percentage of CD4 +V33 +  T  cells in- 
creases substantially following SEA stimulation, as compared 
with the starting population.  The CD4-V33 + population 
also increases after stimulation with SEA, particularly on day 
6 (these cells are most likely CD8 cells that are positive for 
V133 expression).  Whereas GANC  treatment  has no effect 
on cells isolated from the B6 control mouse,  there is a sig- 
nificant decrease in the number of V133 + T  cells in samples 
from the transgenic mouse. On day 4, all V33 + T  cells are 
significantly reduced whereas  predominantly  CD4+V33 + 
cells are affected on day 6.  There are more V33 + cells on 
day 6 as compared with day 4  (Fig. 8). This may represent 
an enrichment of a small population of V33 + cells which 
initially escaped killing by GANC. As expected, there is no 
effect on CD4-V~/3-  T  cells. These cells are most likely B 
cells that  do not express HSK-TK activity. Whereas  there 
is a selective ablation of V133 + T  cells, there is also killing 
of CD4+VI33 -  cells.  The non-V133 CD4 cells that are elim- 
inated are most likely other CD4 cells that respond to SEA 
such as V1311 T  cells (29).  It is interesting to note that al- 
though we generally see an 80-90% suppression of prolifer- 
ation in cell growth assays,  this is not reflected in the de- 
crease  seen  in  the  CD4  T  cell  population.  A  possible 
explanation is that these residual cells are CD4 cells that are 
not synthesizing IL-2 and are therefore not affected by GANC. 
It is also interesting that CD4 + V133 + T  cells are preferen- 
tially eliminated on day 4, whereas a greater percentage of 
CD4+VB3 -  cells are ablated on day 6.  It is likely that the 
V133 +  population  responds  to  SEA  before  other  VI3- 
expressing T  cells. 
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Figure  8.  FACS  |  analysis of V/~3 expression of CD4 cells. 106 CD4- 
enriched  cells were cultured with 105 APC and  100 ng/ml SEA in the 
presence and absence  of 20/~M GANC. Cells were harvested  on days 4 
and 6 and double stained  using a PE-conjugated  anti-CD4 mAb and a 
FITC-conjugated anti-VB3 mAb. Samples were analyzed on a Becton Dick- 
inson FACS  |  Analyzer 1. The CD4 + cells were gated on and the FACS  | 
plot is  only of these cells. 
IL-2-producing Cells Are Required for a Proliferative Response 
to SEA but Are only Partially Required for a Response to Con A. 
To investigate the requirement of IL-2-producing cells in re- 
sponse to mitogens other than SEA, CD4 T  cells from the 
transgenic mouse were stimulated with Con A. Fig. 9 com- 
pares  the  proliferative  response  of CD4  cells  treated  with 
GANC when stimulated with either SEA or Con A. GANC 
reduced proliferation  of transgenic CD4 cells to SEA by 83%. 
When CD4 cells were stimulated with Con A, proliferation 
was suppressed by only 35% in cells from the transgenic mouse 
and 9%  in cells  from a control  mouse (Fig.  9  B). 
,9,  MOUSE  Z  m 
Figure  9.  Suppression  of proliferation  in T  cells activated  with SEA 
and Con A. (A) 5  x  104 CD4-enriched spleen cells were cultured with 
100 ng/ml SEA and 10  ~ APC in the presence or absence of 10/~M GANC. 
Cells were pulsed with [3H]thymidine  (1 ttCi) on day 6 and incorpora- 
tion was measured on day 7. Samples were run in duplicate and the max- 
imum average  cpm  obtained  was  83,154.  (B)  2  x  105  CD4-enriched 
spleen  cells  were cultured  with 2.5/~g/ml Con A and  104 APC in the 
presence or absence of 10 #M GANC. Cells were pulsed with [3H]thymi- 
dine (1 #Ci) on day 3 and incorporation  was measured on day 4. Samples 
were run in duplicate and the maximum average cpm obtained was 329,883. 
The difference in the effect of GANC on proliferation when 
cells are stimulated with Con A as compared with SEA could 
reflect differences  in the mechanisms by which cells are acti- 
vated  by  the  two  mitogens,  or  merely  differences  in  the 
efficiency of killing in the two systems. The proliferation to 
Con A  could involve IL-2-independent  mechanisms;  such 
cells would be insensitive to the effects of GANC.  To test 
this hypothesis, cells were hybridized in situ after activation 
with  either  Con A  or SEA in  the presence  or absence  of 
GANC. Cells were analyzed for IL-2 mRNA expression after 
primary stimulation and after restimulation with the same 
mitogen.  It is striking that the reduction in the proportion 
of cells expressing IL-2 mRNA in the primary cultures is 
nearly identical for both Con A- and SEA-activated cells (Table 
1456  Ablation of ILo2-producing  Cells Table  2.  Frequency  of CD4  T  Cells Positive  for IL-2 mRNA 
Percent  cells expressing 
IL-2 mRNA 
not shown). Therefore, the addition of rlL-2 to CD4 T cells 
treated with GANC does not restore the proliferative response 
to SEA. 
Primary  Restimulated 
Con A-GANC  35 (15)  8 (24) 
Con A plus GANC  9 (10)  4 (10) 
SEA-GANC  19 (15)  10 (16) 
SEA plus GANC  4 (9)  5 (10) 
5  x  104 CD4 cells were stimulated  with either Con A or SEA in the 
presence or absence of GANC. Cultures were either harvested on day 3 
(primary  cultures)  or washed  and restimulated  on day 5 with the same 
mitogen and harvested  on day 6 (restimulated  cultures).  Cytocentrifuge 
preparations  were made and analyzed by in situ hybridization for IL-2 
mRNA production.  The numbers in parentheses refer to the average num- 
ber of grains per mRNA + cell. Grain counts per cell were recorded for 
1,000 cells from 10 microscope fields per slide. Cells were considered posi- 
tive when overlayed  with greater  than  five grains. 
2). Since the efficiency of eliminating cells that produce IL-2 
is the  same for both mitogens,  the difference in the effect 
of GANC on proliferation is not a result of less efficient killing 
of Con A-treated cultures as compared with SEA. These results 
are consistent with there being an IL-2-independent mecha- 
nism of proliferation for Con A which is insensitive to drug 
treatment. 
Upon restimulation,  a small number of cells are capable 
of IL-2 expression following GANC treatment for both Con 
A and SEA (Table 2). These residual ceils appear to be quali- 
tatively different from cells not treated with drug since they 
have a lower grain count and therefore presumably lower IL-2 
mRNA content. These cells may not be susceptible to GANC 
because they produce less IL-2 and are consequently unable 
to proliferate,  which is necessary for killing  with  GANC. 
Consistent  with  this is the fact that  proliferation  of SEA- 
stimulated cells is significantly inhibited  by GANC. 
The Proliferating T Cell Is the Same Cell Making IL-2.  In 
the present  study,  cells  that  produce IL-2 are ablated and, 
as a consequence, proliferation is reduced. If bystander cells 
which require IL-2 for proliferation, but which do not pro- 
duce it,  are  still  present  in  the  culture,  these  cells  could 
proliferate in response to IL-2 since they will not be killed 
by GANC. To test this, 5 U/ml (5 ng/ml) rlL-2 was added 
to CD4 cells stimulated with SEA in the presence or absence 
of GANC. Fig. 10 compares the results of proliferation assays 
carried out using cells from a control (Fig.  10, A  and B) or 
a transgenic  (Fig.  10,  C  and D) mouse incubated with  or 
without  added IL-2.  In the absence of rlL-2,  proliferation 
was suppressed in the transgenic mouse from 67% using 5 
x  104 cells  to  89%  using  1.25  x  104 cells  (Fig.  10  C). 
When  rlL-2  was  present  during  the  incubation  period, 
proliferation  was suppressed from 86%  using  1.25  x  104 
cells to 91% using 2.5  x  104 or 5  x  104 cells (Fig.  10 D). 
The same failure to restore proliferation was obtained when 
10 U/ml (IL-2) was added to GANC-treated CD4 cells (data 
Discussion 
IL-2 has  been shown to be the major growth factor for 
T cells and plays a key role in the clonal expansion of antigen- 
specific T  cells. There are indications,  however, that IL-2 is 
not the sole T cell growth factor and that IL-2-independent 
mechanisms may exist for T  celI proliferation. 
We have established the use of cell ablation to analyze the 
requirement for IL-2-producing cells in the proliferative re- 
sponses to mitogens. Treatment with GANC is highly effec- 
tive  (,'080-90%)  in  the  removal  of IL-2-producing  cells, 
whether measured by suppression of T  cell proliferation or 
IL-2 production, or the elimination of cells expressing IL-2 
mRNA detected by in situ hybridization. The results presented 
here demonstrate  that  IL-2-producing  T  cells are required 
for a proliferative response to the superantigen SEA. We have 
also shown that  proliferation  to SEA is not restored when 
rlL-2 is added to cultures in which IL-2-producing cells have 
been eliminated.  These results indicate that the majority of 
T  cells that proliferate in response to SEA are making IL-2 
and are not bystander cells which require IL-2 for cell growth. 
A less likely explanation which we have not excluded, how- 
ever, is that the IL-2-producing cells provide something other 
than IL-2, which is required for proliferation  by bystander cells. 
The inability of rlL-2 to restore the proliferative response 
to SEA differs  from results reported by Schorle et al.  (19). 
When IL-2 was added to Con A-stimulated splenocytes iso- 
lated from mice that were unable to make IL-2 as a conse- 
quence of a homozygous null mutation  at  the IL-2 locus, 
proliferation  was restored to wild-type levels. However, in 
these IL-2-deficient mice, the cells that respond to IL-2 are 
still present and able to proliferate when exogenous IL-2 is 
added. In the study described here, the cells that require IL-2 
for proliferation  to SEA have been ablated. 
The ablation method used in this study only partially in- 
hibits the proliferative response to Con A, whereas it nearly 
abolishes the response to SEA. Using in situ hybridization, 
we have shown that the efficiency of killing of cells that pro- 
duce IL-2 is the same for Con A and SEA, despite the different 
effect on T  cell proliferation.  This suggests that  a portion 
of the proliferative response to Con A occurs via an alterna- 
tive pathway not requiring IL-2 expression and release. These 
results are consistent with those obtained by Schorle et al. 
(19) using IL-2-deficient mice. Although splenocytes isolated 
from such mice show a marked decrease in their ability to 
respond  to Con A,  there is still a residual proliferative re- 
sponse that is not inhibited by the absence of IL-2. Our results 
also demonstrate  that  residual cells capable of IL-2 expres- 
sion are present after drug treatment  when either mitogen 
is used for stimulation. However, the lower grain count present 
in these cells compared with cells not treated with the drug 
suggests that these cells may be unable to proliferate because 
of a reduced production of IL-2, which renders them insen- 
sitive to GANC. 
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Figure  10.  The addition  of rlL-2 does not restore the proliferative response to SEA.  Various numbers of CD4-enriched  spleen cells were cultured 
with 100 ng/ml SEA and 104 APC in the presence or absence of 10/~M GANC. 5 U/ml rlL-2 was added to half the samples (B and D) at the start 
of culture.  Cells were pulsed  with [SH]thymidine  (1/ICi) on day 6  and incorporation  was measured on day 7. Samples were run in triplicate and 
the SE is given.  The maximum average cpm obtained  were 94,619 (A), 98,350 (B), 115,628 (C), and 139,392 (D). 
It is important that the ablation of T  cells be specific  for 
those cells that are activated and express IL-2. We have shown 
that HSV-TK activity is present in activated T cells but ab- 
sent in B cells.  More importantly, we have shown that the 
V33 + population of T  cells that are activated in the pres- 
ence  of SEA  are  selectively  ablated  whereas  CD4§  - 
cells remain a viable population. In addition, unlike the re- 
sponse to SEA, the proliferative response to Con A  is only 
partially inhibited by drug treatment of stimulated cells. This 
provides additional evidence that we are specifically eliminating 
activated T  cells which are producing IL-2 and not all acti- 
vated T  cells.  The transgenic mice that we have generated 
will therefore be a powerful tool for studying the require- 
ment of IL-2 in specific immune responses, as well as during 
fetal development. We have preliminary data that shows the 
requirement of IL-2-producing cells for an in vitro recall re- 
sponse to KLH (Kamogawa, Y., unpublished results) and for 
the expression of IL-2 in the normal development of T cells 
(Carding, S., unpublished results). Finally,  the selective abla- 
tion of IL-2-producing T cells provides a unique method for 
studying the lineage relationship between  subsets of CD4 
T  cells. 
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